Chen Ying, Tang Xin, Zhu Liran, Wang Yi, Li Gaopeng, Yang Wulin
Department of Breast Surgery, Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Hefei Cancer Hospital of CAS, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Cancer Cell Int. 2025 Aug 18;25(1):306. doi: 10.1186/s12935-025-03942-4.
The N-formyl peptide receptor family (FPRs) is implicated in the progression of diverse cancer types, yet studies specifically exploring their roles in breast cancer remain scarce.
A comprehensive analysis integrating bulk RNA-seq transcriptomics, methylomics, single-cell transcriptomics, and spatial single-cell transcriptomics data was conducted to elucidate the distinctive characteristics of FPRs in breast cancer. This study particularly focused on delineating the e xpression profiles of FPR3 across distinct breast cancer subtypes, while systematically investigating its prognostic implications and association with macrophage polarization patterns in breast cancer patients. Furthermore, molecular docking analysis was performed to screen potential therapeutic compounds targeting FPR3, providing insights into its druggability.
Notably, FPR3 was found to be highly expressed in macrophages within breast cancer tissues, with a notably elevated level in HER2-positive and triple-negative breast cancer (TNBC) subtypes, both of which are associated with poor prognosis. FPR3 expression inversely correlates with promoter methylation levels. Further analysis of pan-cancer immune infiltration patterns uncovered a striking association between FPR3 and macrophage infiltration, as well as their polarization status. Knockdown of FPR3 expression in macrophages markedly enhanced the expression of IL6, TNF-α, and TGF-β, while significantly reducing IL10 levels, indicative of a shift towards an M1-like macrophage phenotype. Through computational molecular docking analyses, Otamixaban and Rivaroxaban emerged as promising candidate inhibitors of FPR3.
These findings underscore the profound infiltration of FPR3 + macrophages in breast cancer patients with adverse prognoses, highlighting FPR3 as a potential therapeutic target for intervening breast cancer aggressiveness.
N-甲酰肽受体家族(FPRs)与多种癌症类型的进展有关,但专门探索其在乳腺癌中作用的研究仍然很少。
进行了一项综合分析,整合了批量RNA测序转录组学、甲基组学、单细胞转录组学和空间单细胞转录组学数据,以阐明FPRs在乳腺癌中的独特特征。本研究特别关注描绘FPR3在不同乳腺癌亚型中的表达谱,同时系统地研究其对乳腺癌患者的预后影响以及与巨噬细胞极化模式的关联。此外,进行了分子对接分析以筛选靶向FPR3的潜在治疗化合物,从而深入了解其可成药特性。
值得注意的是,发现FPR3在乳腺癌组织中的巨噬细胞中高度表达,在HER2阳性和三阴性乳腺癌(TNBC)亚型中水平显著升高,这两种亚型均与预后不良相关。FPR3表达与启动子甲基化水平呈负相关。对泛癌免疫浸润模式的进一步分析发现FPR3与巨噬细胞浸润及其极化状态之间存在显著关联。巨噬细胞中FPR3表达的敲低显著增强了IL6、TNF-α和TGF-β的表达,同时显著降低了IL10水平,表明向M1样巨噬细胞表型转变。通过计算分子对接分析,奥扎米星和利伐沙班成为FPR3有前景的候选抑制剂。
这些发现强调了FPR3 +巨噬细胞在预后不良的乳腺癌患者中的深度浸润,突出了FPR3作为干预乳腺癌侵袭性的潜在治疗靶点。